• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies

    9/11/25 8:00:00 AM ET
    $MASI
    $PHG
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical Electronics
    Health Care
    Get the next $MASI alert in real time by email

    September 11, 2025

    Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, and Masimo (NASDAQ:MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-generation patient monitoring solutions. This expanded agreement reflects our commitment to empower clinicians with smarter, more integrated technologies that support better outcomes across the continuum of care.

    Accelerating access to next-generation monitoring technologies 

    At the heart of the expanded partnership is a joint effort to integrate Masimo's advanced monitoring technologies – including SET® pulse oximetry, Radius PPG, and a range of sensor technology – into Philips' multi-parameter patient monitoring platforms. This integration supports clinicians with reliable data and actionable insights across bedside monitors, central stations, and wearable solutions, while giving them the flexibility to use their preferred measurement technologies within a single, unified system. By embedding these capabilities into Philips' monitoring ecosystem, the collaboration aims to reduce complexity, enhance interoperability, and deliver streamlined tools that support timely decision-making and continuity of care. 

     

    Building on this foundation, Philips and Masimo also plan to collaborate on the development and co-promotion of next-generation monitoring solutions that reflect emerging clinical needs and evolving market demands such as the need for greater patient mobility. These efforts are focused on advancing smart, connected care and expanding access to innovative technologies, including AI algorithms, that have the potential to improve patient care over time. 

     

    "Our priority is helping clinicians deliver the best possible care to their patients, and that means staying ahead of the curve," said Julia Strandberg, Executive Vice President and Business Leader Connected Care at Royal Philips. "This partnership allows us to respond quickly to evolving clinical needs and market trends, integrating proven technologies into solutions that are easy to use, reliable, and scalable."

    "We are excited to continue to partner with Philips to bring Masimo's newest innovations in wearables and artificial intelligence to Philips' platforms," said Katie Szyman, CEO of Masimo. "Expanding our strong, long-standing partnership with Philips allows us to build on our shared legacies of innovation and helps ensure that Masimo's best-in-class technologies reach even more patients. Together, Masimo and Philips will continue to empower clinicians to transform patient care."

    A shared commitment to innovation and impact 

    The renewed partnership underscores both companies' dedication to transforming patient care through meaningful innovation. By bringing together Philips' deep expertise in patient monitoring and Masimo's advanced noninvasive technologies, the collaboration is focused on delivering integrated, clinically validated solutions that scale to meet the needs of healthcare providers. It also aligns with Philips' broader strategy to work with industry-leading partners to enhance care delivery, improve operational efficiency, and support vendor-neutral interoperability across healthcare systems.

    For further information, please contact:

    Mark Groves

    External Relations, Philips

    Tel: +31 631 639 916

    E-mail: [email protected]

    About Royal Philips

    Royal Philips (NYSE:PHG, AEX: PHIA)) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

    Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

    Attachment

    • Philips patient monitors in use


    Primary Logo

    Get the next $MASI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MASI
    $PHG

    CompanyDatePrice TargetRatingAnalyst
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/25/2025Neutral → Outperform
    Exane BNP Paribas
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/20/2025Neutral → Buy
    UBS
    Masimo Corporation
    $MASI
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    Masimo Corporation
    $MASI
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    10/29/2024Underperform → Hold
    Jefferies
    Masimo Corporation
    $MASI
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    5/13/2024Mkt Perform → Outperform
    Bernstein
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    5/7/2024Underperform → Neutral
    Exane BNP Paribas
    More analyst ratings

    $MASI
    $PHG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clairity Raises $43 Million in Series B to Launch First FDA-Authorized AI Platform for Breast Cancer Risk Prediction

    With backing from leading healthcare investors, Clairity accelerates its mission to predict and prevent breast cancer and expand into cardiovascular disease Clairity, Inc., an AI-driven precision health company pioneering image-based risk prediction, today announced the closing of a $43 million Series B financing. The funds will be used to commercialize the company's product, Clairity Breast, the first FDA-authorized artificial intelligence platform that predicts a woman's five-year risk of breast cancer directly from a routine mammogram, and to advance development of Clairity Breast 3D and Clairity Heart, Clairity's next offering focused on predicting cardiovascular risk from the same ro

    11/13/25 9:49:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Reports Third Quarter 2025 Results

    Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371.5 million, representing 8.2% growth on a reported basis; Non-GAAP revenue of $371.2 million, representing 7.6% growth on a constant currency basis(2); GAAP net income per diluted share of $0.99; and Non-GAAP net income per diluted share(2) of $1.32, representing 38% growth versus prior year period. Katie Szyman, Chief Executive Officer of Masimo, said, "In the third quarter, we saw continued positive momentum across our core healthcare business, driven by the power of our innovative pr

    11/4/25 4:05:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

    November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA margin increased by 50 basis points to 12.3% of salesOperating cash flow of EUR 327 million, with a free cash flow of EUR 172 millionPhilips reiterates full-year 2025 outlook, with margin now expected at the upper end of the range Roy Jakobs, CEO of Royal Philips:"In this quarter we maintained our momentum, with AI-powered innovations and long-term partnerships making a real difference for patients and consumers. We drove strong order intake and accelerated sales growth, with sus

    11/4/25 1:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    $MASI
    $PHG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $437,940 worth of shares (3,000 units at $145.98), increasing direct ownership by 168% to 4,790 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/12/25 4:20:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    SEC Filings

    View All

    SEC Form 10-Q filed by Masimo Corporation

    10-Q - MASIMO CORP (0000937556) (Filer)

    11/4/25 5:08:38 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MASIMO CORP (0000937556) (Filer)

    11/4/25 4:09:41 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

    6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

    11/4/25 10:55:41 AM ET
    $PHG
    Medical Electronics
    Health Care

    $MASI
    $PHG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO, Consumer Division Tripodi Blair exercised 15,000 shares at a strike of $142.13 and covered exercise/tax liability with 8,078 shares, increasing direct ownership by 100% to 13,818 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    9/25/25 6:25:25 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Dadswell Charles

    4 - MASIMO CORP (0000937556) (Issuer)

    9/3/25 5:03:29 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Dadswell Charles

    3 - MASIMO CORP (0000937556) (Issuer)

    9/3/25 5:02:35 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philips upgraded by Exane BNP Paribas

    Exane BNP Paribas upgraded Philips from Neutral to Outperform

    2/25/25 7:12:36 AM ET
    $PHG
    Medical Electronics
    Health Care

    Philips upgraded by UBS

    UBS upgraded Philips from Neutral to Buy

    2/20/25 7:05:01 AM ET
    $PHG
    Medical Electronics
    Health Care

    Raymond James reiterated coverage on Masimo with a new price target

    Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

    12/27/24 7:29:29 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Leadership Updates

    Live Leadership Updates

    View All

    Masimo to Host Investor Day on December 3, 2025

    Masimo (NASDAQ:MASI) today announced it will host a meeting with the analyst and investor community at 9:00am PT on Wednesday, December 3, 2025. Presentations will be led by select members of the Executive Leadership Team and will cover an overview of the company's business, market opportunities, innovation pipeline, commercial growth strategy, and long-term financial outlook. The company invites investors to join the event via live webcast, which will be available on the Investor Relations section of its website at https://investor.masimo.com/ under "Events and Presentations" or directly by visiting the following link: Masimo Investor Day webcast. A replay of the webcast and the relate

    10/9/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

    American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

    7/8/25 8:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New AI Rollouts Signal Shift From Hype to Healthcare Reality

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

    6/24/25 9:45:00 AM ET
    $LLY
    $PHG
    $PLTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Electronics
    Computer Software: Prepackaged Software

    $MASI
    $PHG
    Financials

    Live finance-specific insights

    View All

    Masimo Reports Third Quarter 2025 Results

    Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371.5 million, representing 8.2% growth on a reported basis; Non-GAAP revenue of $371.2 million, representing 7.6% growth on a constant currency basis(2); GAAP net income per diluted share of $0.99; and Non-GAAP net income per diluted share(2) of $1.32, representing 38% growth versus prior year period. Katie Szyman, Chief Executive Officer of Masimo, said, "In the third quarter, we saw continued positive momentum across our core healthcare business, driven by the power of our innovative pr

    11/4/25 4:05:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

    November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA margin increased by 50 basis points to 12.3% of salesOperating cash flow of EUR 327 million, with a free cash flow of EUR 172 millionPhilips reiterates full-year 2025 outlook, with margin now expected at the upper end of the range Roy Jakobs, CEO of Royal Philips:"In this quarter we maintained our momentum, with AI-powered innovations and long-term partnerships making a real difference for patients and consumers. We drove strong order intake and accelerated sales growth, with sus

    11/4/25 1:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Masimo to Report Third Quarter 2025 Financial Results after Market Close on Tuesday, November 4

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2025 financial results for the period ended September 27, 2025, after the market closes on Tuesday, November 4, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered

    10/21/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    9/25/24 4:01:23 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    8/30/24 4:56:53 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    7/17/24 5:29:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care